## 단원 III 천식의 진단, 평가 및 감별진단

67. Rhee CK, Yoon Hk Fau - Yoo KH, Yoo Kh Fau - Kim YS, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. (1541-2563 (Electronic)).
68. Diaz-Guzman E, Khosravi M Fau - Mannino DM, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. (1541-2563 (Electronic)).
69. Park HY, Lee SY, Kang D, et al. Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. Respir Res. 2018;19(1):36.
70. Suzuki M, Makita H, Konno S, et al. Asthma-like Features and Clinical Course of Chronic Obstructive Pulmonary Disease: An Analysis from the Hokkaido COPD Cohort Study. American journal of respiratory and critical care medicine. 2016;194(11):1358-1365.
71. Jo YS, Hwang YI, Yoo KH, et al. Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria. J Allergy Clin Immunol Pract. 2020.
72. Maltby S, Gibson PG, Powell H, McDonald VM. Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD. Chest. 2017;151(1):78-89.
73. Hanania NA, Chipps BE, Griffin NM, Yoo B, Iqbal A, Casale TB. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. The Journal of allergy and clinical immunology. 2019;143(4):1629-1633.e1622.
74. Bateman ED, Goehring UM, Richard F, Watz H. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. The Journal of allergy and clinical immunology. 2016;138(1):142-149.e148.
75. Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: Efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35 Suppl:S20-S27.
76. Bardin P, Kanniess F, Gauvreau G, Bredenbroker D, Rabe KF. Roflumilast for asthma: Safety and mechanism of action studies. Pulm Pharmacol Ther. 2015;35 Suppl:S4-S10.
77. McDonald VM, Simpson JI Fau - Higgins I, Higgins I Fau - Gibson PG, Gibson PG. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. (1468-2834 (Electronic)).
78. Pagnoux C, Guilpain C, Guillevin L. Churg-Strauss syndrome. Current opinion in rheumatology. 2007;19(1):25-32.
79. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926-2935.
80. Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol. 2009;23(3):355-366.
81. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26-37.
82. Lane SE, Watts RA, Bentham G, Innes NJ, Scott DG. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 2003;48(3):814-823.
83. Imai H, Nakamoto Y, Hirokawa M, Akihama T, Miura AB. Carbamazepine-induced granulomatous necrotizing angiitis with acute renal failure. Nephron. 1989;51(3):405-408.
84. Dietz A, Hubner C, Andrassy K. [Macrolide antibiotic-induced vasculitis (Churg-Strauss syndrome)]. Laryngorhinootologie. 1998;77(2):111-114.
85. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf. 2007;16(6):620-626.
86. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasakl L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136(2):507-518.
87. Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest. 1995;108(2):320-323.
88. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients.

<PAGE>66